REFINE-MS: A randomised, rater-blind, phase 3 trial to determine the optimal dose frequency of ocrelizumab for patients with relapsing remitting multiple sclerosis using a novel multi-arm multi-stage frequency-optimisation design (REFINE-MS)

Principal Investigator

Prof Gabriele DeLuca

Contact us

Email: dendron@ouh.nhs.uk

IRAS number

1013232